James Lee on the vital role of business development for biotech companies

James Lee received his B.S and M.S. in Structural Biology from
Seoul National University, he held various roles in research,
research planning, and business development at LG Chem. In year
2000, James co-founded Crystal Genomics where he led fundraising
and business development activities. In 2008, he founded Rexbio,
an early-stage biotech startup specialized in discovering and
developing therapeutics and diagnostics for the treatment of
pancreatic cancer.


 


James founded Bridge Biotherapeutics Inc. in 2015 and he
currently serves as the CEO. Bridge has been recognized with the
continuous advancement of clinical-stage programs focused on
pulmonary fibrosis, lung cancer, and immunology. In 2019, James
successfully orchestrated the licensing-out deal with Boehringer
Ingelheim, which marked as one of the largest global deals on a
single compound in Korea.